Abstract
Lipodystrophy is a rare lipid storage disorder that is characterized by a loss of adipose tissue. It can be inherited due to monogenic mutation or acquired by medication and autoimmune illness. Two primary forms of inherited lipodystrophy are congenital generalized lipodystrophy manifested as a near-complete loss of fat tissue since birth and familial partial lipodystrophy with progressive, partial loss of fat tissue during late childhood and puberty. Lipodystrophy results in severe metabolic conditions, including insulin resistance, type 2 diabetes, hepatosteatosis, polycystic ovary syndrome, acanthosis nigricans, and hypertension. This chapter summarizes the symptoms, causes, and treatments of inherited and acquired lipodystrophy.
Keywords
- adipose tissue
- adipogenesis
- metabolic syndrome
- lipid disorders
- ectopic lipid
1. Introduction
In order to survive and adapt to challenging environment, living organisms have equipped themselves with different mechanisms of energy storage that can be accessed when there is a shortage of food supply. In mammals, fat is mainly stored in adipose tissues [1]. There are two types of adipose tissues: white adipose tissue that stores the majority of the body fat and also functions as an endocrine organ and brown adipose tissue that generates the body heat [2]. In adipocytes, fat is stored in lipid droplets (LDs) in the form of neutral lipids, e.g., triacylglycerol (TAG) and cholesteryl ester (CE). White adipocytes contain unilocular LDs that occupy up to 90% of the cytoplasmic space, while brown adipocytes contain multilocular LDs. Obesity is characterized by both increase in the size and number of white adipocytes [3]. Fat storage in white adipose tissue is essential for proper metabolic homeostasis [4]. In contrast, when fat storage in white adipose tissue is compromised or overwhelmed, the ectopic fat accumulation in non-adipose tissues will result in severe metabolic disorders [5].
Lipodystrophy is an extreme fat storage condition, in which white adipose tissue is selectively lost [6]. Partial or generalized loss of fat in this condition causes an array of complications including insulin resistance, type 2 diabetes and acanthosis nigricans, hypertriglyceridemia, hepatic steatosis, hypertension, polycystic ovarian syndrome, and proteinuric kidney disease [7, 8]. The severity of lipodystrophy depends on the level of adipocyte depletion in the body. Fat loss can occur in nearly the entire body known as congenital generalized lipodystrophy (CGL) or partial loss in small and discrete areas known as familial partial lipodystrophy (FPLD). While CGL is manifested early in life at birth or soon after, partial fat loss in FPLD occurs during late childhood and puberty. CGL can be determined by measurements of skinfold thickness with calipers or by whole-body magnetic resonance imaging (MRI) scan [9]. Since lipodystrophy is a monogenetic disorder, it can also be diagnosed and confirmed by genotyping.
Lipodystrophy is a very rare genetic disease (1 in 10 million for CGL). Currently, there have been around 300–500 CGL cases and 1000 FPLD cases reported; however, the number of undiagnosed patients is suspected to be three times more [10]. Nearly 20 loci for different subtypes of lipodystrophy have been identified. These genes are implicated in the regulation of either the development of white adipose tissue or the expansion of LDs in white adipocytes. In this chapter, we will outline these lipodystrophy-causative gene loci as well as describe in brief the acquired condition of lipodystrophy.
2. Genetics of congenital generalized lipodystrophy
There are four different genetic subtypes of CGL that result from different mutations.
2.1 Type 1 CGL (CGL1) and AGPAT2
Mutations that are responsible for CGL1 (Online Mendelian Inheritance in Man [OMIM] #608594) occur in the region of 1-acylglycerol-3-phosphate O-acyltransferase 2 (
AGPAT2 is a member of lysophosphatidic acid acyltransferases (LPAATs) including AGPAT family (AGPAT1–AGPAT11) and others such as CGI-58 and endophilin [17]. In fact, AGPAT2 was identified with AGPAT1 by searching an EST database for human homologs of yeast LPAAT in 1997 [18]. There are 11 isoforms of AGPATs that are involved in the de novo synthesis of phospholipids (PLs) and triacylglycerol from glycerol-3-phosphate (G3P).
In adipose tissue, the synthesis of PLs and TAG begins with the acylation of G3P with FA-CoA by glycerol phosphate acyltransferase (GPAT) at the SN1 position to form 1-acylglycerol-3-phosphate or lysophosphatidic acid (LPA). Then AGPAT2 catalyzes the conversion of LPA into phosphatidic acid (PA) via an acylation reaction at the SN2 position. PA is a pivotal intracellular signaling lipid for it sits at the branching point of de novo PL and TAG synthesis pathway and acts as a precursor for the lipin-mediated production of diacylglycerol (DAG), followed by phosphatidylcholine (PC), phosphatidylethanolamine (PE), and TAG, and as the substrate for the cytidine diphosphate synthase (CDS)-mediated generation of cytidine diphosphate diacylglycerol (CDP-DAG), followed by phosphatidylinositol (PI), phosphatidylglycerol (PG), and cardiolipin [21]. PA is a cone-shaped lipid that has the capacity to alter the curvature of the membranes, and it has been shown to mediate membrane fusion in both soluble N-ethylmaleimide-sensitive factor attachment protein (NSF)-receptor (SNARE)-dependent and SNARE-independent fashions [22, 23]. It has been implicated in the fusion of multiple LDs to form a gigantic LD [24]. In addition, PA is believed to be an endogenous antagonist of peroxisome proliferator-activated receptor gamma (PPARγ) that is the master transcription factor in adipocyte differentiation [25]. The malfunctioned
Ablation of
In addition, these BAT-derived preadipocytes exhibit an increased expression of autophagy-related proteins but a decreased autophagic flux [35]. In isolated muscle-derived multipotent cells (MDMCs) from CGL1 patients and 3T3-L1 preadipocyte cells with the knockdown of AGPAT2, cell death also proceeds during adipogenesis, which might be associated with defective Akt activation as a result of altered PI composition [36, 37]. The constitutively active Akt and PPARγ agonist pioglitazone partially rescued the adipogenic defect in the
2.2 Type 2 CGL (CGL2) and SEIPIN
In CGL2 (OMIM #269700), mutations happen in the
Unlike patients with CGL1, patients with CGL2 suffer a near-total loss of both metabolically active and mechanical adipose tissues [41]. In addition, these patients have significantly low median serum levels of leptin (0.01 ng/ml) and adiponectin (3.3 μg/ml) as compared to normal healthy individuals who had median serum levels of 4.6 ng/ml and 7.8 μg/ml for leptin and adiponectin, respectively [42]. Also, they suffer cardiomyopathy and mild mental retardation in a more prevalent way [7, 8, 43]. One single patient with CGL2 has been reported to have teratozoospermia, a condition characterized by sperm defects including abnormalities in sperm morphology and bundled sperm with two or more sperms joined together by large ectopic LDs [44]. Additionally, three patients in a family from Pakistan with
SEIPIN is a 398 amino acid transmembrane protein in the endoplasmic reticulum (ER), which regulates the transport of macromolecules including proteins and lipids between the ER and the LD [47]. Therefore, it plays a role as a docking protein to regulate LD biogenesis and adipogenesis [48, 49]. Seipin, an integral ER membrane, participates in lipid homeostasis via various complex mechanisms. One of them is to assist LD assembly and fusion as well as adipocyte differentiation [50]. In fact, SEIPIN deficiency in mammals or its yeast ortholog Fld1p/Sei1p can lead to changes in LD morphology, manifested as clustering of multiple small LDs or supersized LDs [5]. Recently, SEIPIN/Fld1p has been found to be stabilized to ER-LD contacts to assist the protein and lipid trafficking into growing LDs. SEIPIN strengthens the contact site between ER and LD to regulate the growth of immature LDs [51]. The protein might also be involved in PL and TAG synthesis by its binding and interaction with phosphatidic acid phosphatase lipin-1 and AGPAT2 [52, 53].
2.3 Type 3 CGL (CGL3) and CAV1
CGL3 (OMIM #612526) is induced by mutations in the
Caveolin-1 is the scaffolding protein primarily constituting specialized vesicular invaginations of 50–100 nm called caveolae [1, 36]. It was discovered by Anderson Lab in 1992 [65, 66]. Its potential function in vesicle transport was reported by Glenney using cDNA encoding caveolin-1 from lungs [67]. There are three caveolin isoforms: CAV1, CAV2, and CAV3. While CAV3 is muscle specific, CAV1 and CAV2 are predominantly expressed in adipose tissue, endothelial cells, and fibroblasts [68, 69]. As the main component of caveolae, caveolin-1 plays an essential role in the caveolae assembly alongside with other caveolar proteins, such as cavin1–cavin4, Pacsin2, and EH domain-containing 2 (EHD2) [70]. In addition to its essential role in caveolae formation, caveolin-1 is also a key determinant of normal lipid homeostasis, vesicular trafficking, and signaling transduction [71]. Caveolae plays a regulatory role in maintaining the integrity and function of the LDs as well as binding and transporting fatty acids and cholesterol by budding off the plasma membrane [70]. Moreover, they serve as a platform for augmenting insulin and PKA signaling [72]. In adipocyte cells, the expression of caveolin-1 is increased 10-fold during adipogenesis [73, 74]. The abundance level of caveolin-1 determines the PL and surface protein composition in LDs and the LD growth. In fact, the expression of
Similar to caveolin-1 deficiency, lacking another caveolar protein cavin-1 in humans also causes another type of congenital generalized lipodystrophy (type 4 CGL) [76, 77, 78]. Interestingly, subcutaneous injection of caveolin-1 overexpressed preadipocytes could form fat pads and larger adipocytes [75]. Both caveolin-1 and cavin-1 are the strong indicators of adipogenic differentiation in human tumors and liposarcoma [79]. Taken together, these data indicate the critical role of adipocyte caveolae in adipose tissue development.
2.4 Type 4 CGL (CGL4) and PTRF
CGL4 (OMIM #613327) is an autosomal recessive condition caused by mutations in the
As mentioned before, cavin-1 interacts with caveolin proteins to form caveolae and to mediate cellular trafficking and lipid turnover [70, 85]. Cavin-1 can stabilize caveolae and caveolin proteins probably via its interactions with cytoskeleton [20]. In agreement with this finding,
3. Familial partial dystrophy
3.1 Type 1 FPLD (FPLD1)
Type 1 FPLD (OMIM #608600), also known as Köbberling-type lipodystrophy, was first reported by Köbberling et al. in 1971 [97]. The syndrome manifests loss of subcutaneous fat in the extremities and gluteus, with normal or increased fat deposition in the face, neck, and trunk [97]. The ratio of skin thickness from the abdomen to the thigh is significantly higher in these subjects, which can be used as a diagnostic method [98]. Diabetes and other metabolic complications including hypertension, insulin resistance, and severe hypertriglyceridemia develop during adulthood, with higher severity in women than men [98, 99]. Similar to other types of lipodystrophy, FPLD1 is an extremely rare genetic condition whose chance of occurrence is 1 in 15 million [6, 36]. Unfortunately, the causative loci for FPLD1 have not been identified to unravel the underlying genetic mechanism of the syndrome.
3.2 Type 2 FPLD (FPLD2) and LMNA
FPLD2 (OMIM #151660) is an autosomal dominant condition that is caused by heterozygous mutations in the
Most cases of FPLD2 are caused by mutations in the lamin A/lamin C (
The
Lamin A is maturated from pre-lamin A via multiple-step posttranslational modifications [114]. This process involves a cleavage reaction carried out by an endoplasmic reticulum membrane protease full name ZMPSTE24 located on chromosome 1p34 [115]. Mutations in ZMPSTE24 have been shown to cause mandibuloacral dysplasia type B and autosomal-dominant FPLD2, due to the lack of functional lamin A [116]. Nonetheless, the question as to whether there is an accumulation of pre-lamin A remains controversial. On the one hand, using lamin A/lamin C antibodies and pre-lamin A-specific monoclonal antibodies, one recent study has shown that fibroblasts carrying lipodystrophy-related LMNA mutations (R482W, I299V, C591F, T528 M) do not exhibit an accumulation of pre-lamin A as compared with their WT counterpart [117]. On the other hand, one prior study has demonstrated that the pre-lamin A level is upregulated in
3.3 Type 3 FPLD (FPLD3) and PPRAG
FPLD3 (OMIM #151660) is caused by mutations in the
FPLD3 patients with PPARγ-induced FPLD suffer metabolic disorders including hypertriglyceridemia, insulin resistance with raised serum triglyceride and cholesterol levels and raised aminotransferase, and γ-glutamyltranspeptidase activities as well as manifest the symptoms of FPLD including subcutaneous fat loss from the arms, muscular hypertrophy in the legs, and arterial hypertension while having the subcutaneous fat buildup in the face, chin, trunk, and abdomen [128].
3.4 Type 4 FPLD (FPLD4) and PLIN1
It has been reported that null mutations in the
3.5 Type 5 FPLD (FPLD5) and CIDEC
The rare FPLD5 (OMIM #615238) is caused by a homozygous nonsense mutation in the LD protein cell death-inducing Dffa-like effector C (
3.6 Type 6 FPLD (FPLD6) and LIPE
Exome sequencing has revealed another novel case of FPLD6 (OMIM #615980) that is caused by a homozygous nonsense mutation in the
3.7 Type 7 FPLD (FPLD7) and CAV1
FPLD7 (OMIM #606721) is also caused by the mutation in the
4. Acquired partial lipodystrophy (APL)
4.1 Barraquer-Simons syndrome
Barraquer-Simons syndrome (OMIM #608709) is named after Barraquer and Simons who first described the disease in the 1900s. Unlike other lipodystrophies, Barraquer-Simons syndrome occurs not due to inherited genetic mutations but normally derives from an acute viral transfection, such as measles [60]. Barraquer-Simons syndrome is extremely rare, with approximately 250 cases that have been reported in the literature with a male-to-female ratio of 1:4 [137]. The syndrome results in loss of subcutaneous fat mainly in the upper part of the body (face, neck, arms, and thorax) and upper abdomen; however, some adipose tissues are preserved in the gluteal regions and lower extremities [138]. Fortunately, Barraquer-Simons syndrome does not normally induce other metabolic complications such as insulin resistance, diabetes, and hypertriglyceridemia [137].
4.2 Highly active antiretroviral therapy (HAART)-induced lipodystrophy (LD-HIV)
LD-HIV can develop in some HIV-infected individuals who are undergoing antiretroviral therapy of more than 2 years [139]. Several cases have been reported since 1998 [140]. The toxicity of the treatment might result from HIV-1 protease inhibitors and nucleoside reverse-transcriptase inhibitors [141]. The latter ones have been shown to disrupt lipid metabolism and mitochondrial functions [141]. In patients with LD-HIV, subcutaneous fat loss occurs in the arms, legs, and face throughout the treatment course and does not cease after the therapy is discontinued [139]. Fortunately, this type of APL does not result in diabetes and insulin resistance, but some individuals might experience some conditions such as hypertriglyceridemia and coronary heart disease [139].
5. Management
Patients with lipodystrophy normally seek medical treatments toward the specific symptoms that they encounter. Since the disease affects its patients in multiple aspects, care and management require a multidisciplinary team involving pediatricians, surgeons, cardiologists, endocrinologists, nutritionists, and psychiatrists [20]. Mental health supports should also be made to patients who suffer depressions from the diagnosis and anxieties about their appearance [142]. In addition, special education might be necessary for those who have an intellectual disability [142]. Furthermore, such cosmetic surgery as reconstructive facial surgery and bilateral gluteus maximus muscle flap advance might benefit the patients in improving their appearance and quality of life [20].
Dietary restriction is of paramount importance in the disease management. Particularly, those with CGL should follow a high-carb and low-fat diet, since it can raise very-low-density lipoprotein (VLDL) TAG levels while alleviating chylomicronemia [143]. Sufficient energy supply along with regular exercise is highly important in children with CGL to ensure their normal growth [20]. However, strenuous exercise is not recommended for CGL4 patients who can be treated with β-adrenergic blockers along with other antiarrhythmic medications to prevent catecholaminergic polymorphic ventricular tachycardia [144]. Also, in this case, an implantable pacemaker or defibrillator can be quite beneficial [144]. It remains unclear whether patients with CGL2 and cardiomyopathy should restrict exercise [145].
The first-line therapy for diabetes mellitus, such as metformin and sulphonylureas, can be prescribed to patients with CGL [146]. The lack of subcutaneous fat in the abdomen and thighs might pose a potential barrier for insulin injection, and the patients might necessitate higher doses of insulin [147]. Furthermore, kidney damage such as diabetic nephropathy and end-stage renal disease might occur in patients with long-standing diabetes as the result high blood glucose exposure. Treatments for such condition might involve hemodialysis and kidney transplantation [20].
Metreleptin can be a promising therapeutic drug in the near future as recent studies have shown its potency in improving metabolic complications involving diabetes mellitus, hypertriglyceridemia, and hepatic steatosis in CGL [146, 148, 149, 150, 151]. In fact, 63% reduction in circulating levels of TAG along with 30% increase in insulin sensitivity, and 20% reduction in liver volume are observed in seven patients treated with metreleptin over the period of 4 months [20]. Three patients with CGL2 and two patients with CGL treated with recombinant leptin therapy in Japan during the treatment course of 36 months have shown ameliorated fasting glucose and TAG levels as well as increased insulin sensitivity [152]. Metreleptin therapy can also reduce symptoms of other conditions such as macroalbuminuria, microalbuminuria, and hyperfiltration as well as improve the balance in sex hormone profile [151, 152]. Patients treated with metreleptin might suffer such adverse effects as hypoglycemia, headache, nausea, decreased weight, and abdominal pain [153, 154]. In addition, there is a rare possibility that antileptin antibodies might develop severe infections [154]. Metreleptin therapy can reduce appetite signaled from the hypothalamus, as
6. Conclusions
Lipodystrophy is a rare genetic disease characterized by near-total loss or partial loss of body fat. The syndrome can result in an array of metabolic complications such as insulin resistance, type 2 diabetes, hypertriglyceridemia, and hepatic steatosis. The disease is managed with dietary restriction and exercise programs in line with the leptin therapy.
References
- 1.
Robbins AL, Savage DB. The genetics of lipid storage and human lipodystrophies. Trends in Molecular Medicine. 2015; 21 (7):433-438 - 2.
Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: An endocrine organ. Archives of Medical Science: AMS. 2013; 9 (2):191-200 - 3.
Jo J et al. Hypertrophy and/or hyperplasia: Dynamics of adipose tissue growth. PLoS Computational Biology. 2009; 5 (3):e1000324-e1000324 - 4.
Cohen P, Spiegelman BM. Cell biology of fat storage. Molecular Biology of the Cell. 2016; 27 (16):2523-2527 - 5.
Qi Y, Sun L, Yang H. Lipid droplet growth and adipocyte development: Mechanistically distinct processes connected by phospholipids. Biochimica et Biophysica Acta (BBA)—Molecular and Cell Biology of Lipids. 2017; 1862 (10, Part B):1273-1283 - 6.
Garg A. Acquired and inherited lipodystrophies. New England Journal of Medicine. 2004; 350 (12):1220-1234 - 7.
Agarwal AK et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. The Journal of Clinical Endocrinology and Metabolism. 2003; 88 (10):4840-4847 - 8.
Van Maldergem L et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. Journal of Medical Genetics. 2002; 39 (10):722-733 - 9.
Garg A. Lipodystrophies: Genetic and acquired body fat disorders. The Journal of Clinical Endocrinology & Metabolism. 2011; 96 (11):3313-3325 - 10.
Brown WV et al. JCL roundtable: Diagnosis and clinical management of lipodystrophy. Journal of Clinical Lipidology. 2016; 10 (4):728-736 - 11.
Agarwal AK et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nature Genetics. 2002; 31 (1):21-23 - 12.
Garg A. Clinical review#: Lipodystrophies: Genetic and acquired body fat disorders. The Journal of Clinical Endocrinology and Metabolism. 2011; 96 (11):3313-3325 - 13.
Haghighi A et al. Congenital generalized lipodystrophy: Identification of novel variants and expansion of clinical spectrum. Clinical Genetics. 2016; 89 (4):434-441 - 14.
Rostami P et al. AGPAT2 gene mutation in a child with Berardinelli-Seip congenital lipodystrophy syndrome. Annales d’endocrinologie. 2013; 74 (1):59-61 - 15.
Haghighi A et al. Identification of a novel nonsense mutation and a missense substitution in the AGPAT2 gene causing congenital generalized lipodystrophy type 1. European Journal of Medical Genetics. 2012; 55 (11):620-624 - 16.
Cortes VA et al. Divergent metabolic phenotype between two sisters with congenital generalized lipodystrophy due to double AGPAT2 homozygous mutations. A clinical, genetic and in silico study. PLoS One. 2014; 9 (1):e87173 - 17.
Nagle CA, Klett EL, Coleman RA. Hepatic triacylglycerol accumulation and insulin resistance. Journal of Lipid Research. 2009; 50 (Suppl):S74-S79 - 18.
West J et al. Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that enhance cytokine-induced signaling responses in cells. DNA and Cell Biology. 1997; 16 (6):691-701 - 19.
Gale SE et al. A regulatory role for 1-acylglycerol-3-phosphate-O-acyltransferase 2 in adipocyte differentiation. The Journal of Biological Chemistry. 2006; 281 (16):11082-11089 - 20.
Patni N, Garg A. Congenital generalized lipodystrophies—New insights into metabolic dysfunction. Nature Reviews. Endocrinology. 2015; 11 (9):522-534 - 21.
Qi Y et al. CDP-diacylglycerol synthases regulate the growth of lipid droplets and adipocyte development. Journal of Lipid Research. 2016; 57 (5):767-780 - 22.
Choi SY et al. A common lipid links Mfn-mediated mitochondrial fusion and SNARE-regulated exocytosis. Nature Cell Biology. 2006; 8 (11):1255-1262 - 23.
Vitale N et al. Phospholipase D1: A key factor for the exocytotic machinery in neuroendocrine cells. The EMBO Journal. 2001; 20 (10):2424-2434 - 24.
Paar M et al. Remodeling of lipid droplets during lipolysis and growth in adipocytes. The Journal of Biological Chemistry. 2012; 287 (14):11164-11173 - 25.
Moseti D, Regassa A, Kim W-K. Molecular regulation of adipogenesis and potential anti-adipogenic bioactive molecules. International Journal of Molecular Sciences. 2016; 17 (1):124 - 26.
Beigneux AP et al. Agpat6—A novel lipid biosynthetic gene required for triacylglycerol production in mammary epithelium. Journal of Lipid Research. 2006; 47 (4):734-744 - 27.
Buhman KK et al. DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. The Journal of Biological Chemistry. 2002; 277 (28):25474-25479 - 28.
Hammond LE et al. Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition. Molecular and Cellular Biology. 2002; 22 (23):8204-8214 - 29.
Stone SJ et al. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. The Journal of Biological Chemistry. 2004; 279 (12):11767-11776 - 30.
Vergnes L et al. Agpat6 deficiency causes subdermal lipodystrophy and resistance to obesity. The Journal of Lipid Research. 2006; 47 (4):745-754 - 31.
Cautivo KM et al. AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue. Molecular Metabolism. 2016; 5 (7):491-505 - 32.
Cortes VA et al. Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell Metabolism. 2009; 9 (2):165-176 - 33.
Agarwal AK et al. Human 1-acylglycerol-3-phosphate O-acyltransferase isoforms 1 and 2: Biochemical characterization and inability to rescue hepatic steatosis in Agpat2(-/-) gene lipodystrophic mice. The Journal of Biological Chemistry. 2011; 286 (43):37676-37691 - 34.
Sankella S et al. Hepatic gluconeogenesis is enhanced by phosphatidic acid which remains uninhibited by insulin in lipodystrophic Agpat2−/− mice. The Journal of Biological Chemistry. 2014; 289 (8):4762-4777 - 35.
Fernandez-Galilea M et al. AGPAT2 deficiency impairs adipogenic differentiation in primary cultured preadipocytes in a non-autophagy or apoptosis dependent mechanism. Biochemical and Biophysical Research Communications. 2015; 467 (1):39-45 - 36.
Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. Journal of Human Genetics. 2014; 59 (1):16-23 - 37.
Subauste AR et al. Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations. Diabetes. 2012; 61 (11):2922-2931 - 38.
Cortes VA et al. Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2−/− lipodystrophic mice independent of hepatocyte leptin receptors. Journal of Lipid Research. 2014; 55 (2):276-288 - 39.
Magré J et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nature Genetics. 2001; 28 (4):365-370 - 40.
Liu L et al. Adipose-specific knockout of SEIPIN/BSCL2 results in progressive lipodystrophy. Diabetes. 2014; 63 (7):2320 - 41.
Simha V, Garg A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. The Journal of Clinical Endocrinology and Metabolism. 2003; 88 (11):5433-5437 - 42.
Haque WA et al. Serum adiponectin and leptin levels in patients with lipodystrophies. The Journal of Clinical Endocrinology & Metabolism. 2002; 87 (5):2395-2398 - 43.
Akinci B et al. Natural history of congenital generalized lipodystrophy: A nationwide study from Turkey. The Journal of Clinical Endocrinology and Metabolism. 2016; 101 (7):2759-2767 - 44.
Lungu AO et al. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. The Journal of Clinical Endocrinology and Metabolism. 2012; 97 (2):563-567 - 45.
Schuster J et al. Exome sequencing circumvents missing clinical data and identifies a BSCL2 mutation in congenital lipodystrophy. BMC Medical Genetics. 2014; 15 :71 - 46.
Windpassinger C et al. Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nature Genetics. 2004; 36 (3):271-276 - 47.
Agarwal AK, Garg A. Seipin: A mysterious protein. Trends in Molecular Medicine. 2004; 10 (9):440-444 - 48.
Yang WL et al. BSCL2/seipin regulates adipogenesis through actin cytoskeleton remodelling. Human Molecular Genetics. 2014; 23 (2):502-513 - 49.
Cartwright BR et al. Seipin performs dissectible functions in promoting lipid droplet biogenesis and regulating droplet morphology. Molecular Biology of the Cell. 2015; 26 (4):726-739 - 50.
Szymanski KM et al. The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104 (52):20890-20895 - 51.
Salo VT et al. Seipin regulates ER-lipid droplet contacts and cargo delivery. The EMBO Journal. 2016; 35 (24):2699-2716 - 52.
Talukder MMU et al. Seipin oligomers can interact directly with AGPAT2 and lipin 1, physically scaffolding critical regulators of adipogenesis. Molecular Metabolism. 2015; 4 (3):199-209 - 53.
Sim MFM et al. Analysis of naturally occurring mutations in the human lipodystrophy protein seipin reveals multiple potential pathogenic mechanisms. Diabetologia. 2013; 56 (11):2498-2506 - 54.
Cui X et al. Seipin ablation in mice results in severe generalized lipodystrophy. Human Molecular Genetics. 2011; 20 (15):3022-3030 - 55.
Chen W et al. Altered lipid metabolism in residual white adipose tissues of Bscl2 deficient mice. PLoS One. 2013; 8 (12):e82526 - 56.
Prieur X et al. Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice. Diabetologia. 2013; 56 (8):1813-1825 - 57.
Chen W et al. Molecular mechanisms underlying fasting modulated liver insulin sensitivity and metabolism in male lipodystrophic Bscl2/Seipin-deficient mice. Endocrinology. 2014; 155 (11):4215-4225 - 58.
Chen W et al. Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation. Molecular and Cellular Biology. 2012; 32 (6):1099-1111 - 59.
Boutet E et al. Seipin deficiency alters fatty acid Δ9 desaturation and lipid droplet formation in Berardinelli-Seip congenital lipodystrophy. Biochimie. 2009; 91 (6):796-803 - 60.
Kim CA et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. The Journal of Clinical Endocrinology and Metabolism. 2008; 93 (4):1129-1134 - 61.
Cao H et al. Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. Lipids in Health and Disease. 2008; 7 :3 - 62.
Garg A et al. Whole exome sequencing identifies de novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome. American Journal of Medical Genetics. Part A. 2015; 167A (8):1796-1806 - 63.
Schrauwen I et al. A frame-shift mutation in CAV1 is associated with a severe neonatal progeroid and lipodystrophy syndrome. PLoS One. 2015; 10 (7):e0131797 - 64.
Han B et al. Characterization of a caveolin-1 mutation associated with both pulmonary arterial hypertension and congenital generalized lipodystrophy. Traffic. 2016; 17 (12):1297-1312 - 65.
Rothberg KG et al. Caveolin, a protein component of caveolae membrane coats. Cell. 1992; 68 (4):673-682 - 66.
Brown MS, Goldstein JL. Richard G.W. Anderson (1940-2011) and the birth of receptor-mediated endocytosis. The Journal of Cell Biology. 2011; 193 (4):601-603 - 67.
Glenney JR Jr. The sequence of human caveolin reveals identity with VIP21, a component of transport vesicles. FEBS Letters. 1992; 314 (1):45-48 - 68.
Williams TM, Lisanti MP. The caveolin proteins. Genome Biology. 2004; 5 (3):214-214 - 69.
Stan RV. Structure of caveolae. Biochimica et Biophysica Acta (BBA)—Molecular. Cell Research. 2005; 1746 (3):334-348 - 70.
Shvets E, Ludwig A, Nichols BJ. News from the caves: Update on the structure and function of caveolae. Current Opinion in Cell Biology. 2014; 29 :99-106 - 71.
Fridolfsson HN et al. Regulation of intracellular signaling and function by caveolin. FASEB Journal. 2014; 28 (9):3823-3831 - 72.
Cohen AW et al. Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes. 2004; 53 (5):1261-1270 - 73.
Parton RG, del Pozo MA. Caveolae as plasma membrane sensors, protectors and organizers. Nature Reviews Molecular Cell Biology. 2013; 14 (2):98-112 - 74.
Razani B, Lisanti MP. Caveolin-deficient mice: Insights into caveolar function human disease. The Journal of Clinical Investigation. 2001; 108 (11):1553-1561 - 75.
Briand N et al. Caveolin-1 expression and cavin stability regulate caveolae dynamics in adipocyte lipid store fluctuation. Diabetes. 2014; 63 (12):4032-4044 - 76.
Ardissone A et al. Novel PTRF mutation in a child with mild myopathy and very mild congenital lipodystrophy. BMC Medical Genetics. 2013; 14 :89 - 77.
Dwianingsih EK et al. A Japanese child with asymptomatic elevation of serum creatine kinase shows PTRF-CAVIN mutation matching with congenital generalized lipodystrophy type 4. Molecular Genetics and Metabolism. 2010; 101 (2-3):233-237 - 78.
Rajab A et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genetics. 2010; 6 (3):e1000874 - 79.
Codenotti S et al. Caveolin-1, Caveolin-2 and Cavin-1 are strong predictors of adipogenic differentiation in human tumors and cell lines of liposarcoma. European Journal of Cell Biology. 2016; 95 (8):252-264 - 80.
Zhao Y-Y et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. The Journal of Clinical Investigation. 2009; 119 (7):2009-2018 - 81.
Asterholm IW et al. Altered mitochondrial function and metabolic inflexibility associated with loss of caveolin-1. Cell Metabolism. 2012; 15 (2):171-185 - 82.
Martin S et al. Caveolin-1 deficiency leads to increased susceptibility to cell death and fibrosis in white adipose tissue: Characterization of a lipodystrophic model. PLoS One. 2012; 7 (9):e46242 - 83.
Rajab A et al. Heterogeneity for congenital generalized lipodystrophy in seventeen patients from Oman. American Journal of Medical Genetics. 2002; 110 (3):219-225 - 84.
Heathcote K et al. Molecular analysis of Berardinelli-Seip congenital lipodystrophy in Oman: Evidence for multiple loci. Diabetes. 2002; 51 (4):1291-1293 - 85.
Hayashi YK et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. The Journal of Clinical Investigation. 2009; 119 (9):2623-2633 - 86.
Simha V et al. Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability. American Journal of Medical Genetics. Part A. 2008; 146A (18):2318-2326 - 87.
Shastry S et al. Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. American Journal of Medical Genetics. Part A. 2010; 152A (9):2245-2253 - 88.
Akinci G et al. Spectrum of clinical manifestations in two young Turkish patients with congenital generalized lipodystrophy type 4. European Journal of Medical Genetics. 2016; 59 (6-7):320-324 - 89.
Salle-Teyssieres L et al. Maladaptative autophagy impairs adipose function in congenital generalized ipodystrophy due to Cavin-1 Deficiency. The Journal of Clinical Endocrinology and Metabolism. 2016; 101 (7):2892-2904 - 90.
Jelani M et al. Novel nonsense mutation in the PTRF gene underlies congenital generalized lipodystrophy in a consanguineous Saudi family. European Journal of Medical Genetics. 2015; 58 (4):216-221 - 91.
Murakami N et al. Congenital generalized lipodystrophy type 4 with muscular dystrophy: Clinical and pathological manifestations in early childhood. Neuromuscular Disorders. 2013; 23 (5):441-444 - 92.
Liu L et al. Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. Cell Metabolism. 2008; 8 (4):310-317 - 93.
Liu L, Pilch PF. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. The Journal of Biological Chemistry. 2008; 283 (7):4314-4322 - 94.
Jansa P et al. Cloning and functional characterization of PTRF, a novel protein which induces dissociation of paused ternary transcription complexes. The EMBO Journal. 1998; 17 (10):2855-2864 - 95.
Liu L, Pilch PF. PTRF/Cavin-1 promotes efficient ribosomal RNA transcription in response to metabolic challenges. Elife. 2016; 5 :e17508 - 96.
Ding SY et al. Pleiotropic effects of cavin-1 deficiency on lipid metabolism. The Journal of Biological Chemistry. 2014; 289 (12):8473-8483 - 97.
Kobberling J, Dunnigan MG. Familial partial lipodystrophy: Two types of an X linked dominant syndrome, lethal in the hemizygous state. Journal of Medical Genetics. 1986; 23 (2):120-127 - 98.
Herbst KL et al. Kobberling type of familial partial lipodystrophy: An underrecognized syndrome. Diabetes Care. 2003; 26 (6):1819-1824 - 99.
Garg A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). The Journal of Clinical Endocrinology and Metabolism. 2000; 85 (5):1776-1782 - 100.
Garg A, Peshock RM, Fleckenstein JL. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). The Journal of Clinical Endocrinology and Metabolism. 1999; 84 (1):170-174 - 101.
Shackleton S et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nature Genetics. 2000; 24 (2):153-156 - 102.
Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Human Molecular Genetics. 2000; 9 (1):109-112 - 103.
Scharner J et al. Mapping disease-related missense mutations in the immunoglobulin-like fold domain of lamin A/C reveals novel genotype-phenotype associations for laminopathies. Proteins. 2014; 82 (6):904-915 - 104.
Lanktree M et al. Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2; MIM 151660). Clinical Genetics. 2007; 71 (2):183-186 - 105.
Chan D et al. Familial partial lipodystrophy presenting as metabolic syndrome. Journal of Clinical Lipidology. 2016; 10 (6):1488-1491 - 106.
Madej-Pilarczyk A et al. Limb-girdle muscular dystrophy with severe heart failure overlapping with lipodystrophy in a patient with LMNA mutation p.Ser334del. Journal of Applied Genetics. 2017; 58 (1):87-91 - 107.
Guo X et al. A case of novel Lamin A/C mutation manifesting as atypical progeroid syndrome and cardiomyopathy. Canadian Journal of Cardiology. 2016; 32 (9):1166, e1129-e1131 - 108.
Ambrosi P et al. A novel overlapping phenotype characterized by lipodystrophy, mandibular dysplasia, and dilated cardiomyopathy associated with a new mutation in the LMNA gene. International Journal of Cardiology. 2016; 209 :317-318 - 109.
Kutbay NO et al. A case of familial partial lipodystrophy caused by a novel lamin A/C (LMNA) mutation in exon 1 (D47N). European Journal of Internal Medicine. 2016; 29 :37-39 - 110.
Chirico V et al. LMNA gene mutation as a model of cardiometabolic dysfunction: From genetic analysis to treatment response. Diabetes and Metabolism. 2014; 40 (3):224-228 - 111.
Lloyd DJ, Trembath RC, Shackleton S. A novel interaction between lamin A and SREBP1: Implications for partial lipodystrophy and other laminopathies. Human Molecular Genetics. 2002; 11 (7):769-777 - 112.
Vadrot N et al. The p.R482W substitution in A-type lamins deregulates SREBP1 activity in Dunnigan-type familial partial lipodystrophy. Human Molecular Genetics. 2015; 24 (7):2096-2109 - 113.
Liao CY et al. Rapamycin reverses metabolic deficits in Lamin A/C-deficient mice. Cell Reports. 2016; 17 (10):2542-2552 - 114.
Davies BSJ et al. The posttranslational processing of prelamin A and disease. Annual Review of Genomics and Human Genetics. 2009; 10 :153-174 - 115.
Lucas-Herald AK et al. Proteomic evidence of biological aging in a child with a compound heterozygous ZMPSTE24 mutation. Proteomics - Clinical Applications. 2019; 13 (2):e1800135-e1800135 - 116.
Novelli G et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. American Journal of Human Genetics. 2002; 71 (2):426-431 - 117.
Tu Y et al. LMNA missense mutations causing familial partial lipodystrophy do not lead to an accumulation of prelamin A. Nucleus. 2016; 7 (5):512-521 - 118.
Barroso I et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999; 402 (6764):880-883 - 119.
Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy. The Journal of Clinical Endocrinology and Metabolism. 2002; 87 (1):408 - 120.
Hegele RA et al. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes. 2002; 51 (12):3586 - 121.
Al-Shali K et al. A single-base mutation in the peroxisome proliferator-activated receptor γ4 promoter associated with altered in vitro expression and partial lipodystrophy. The Journal of Clinical Endocrinology and Metabolism. 2004; 89 (11):5655-5660 - 122.
Agostini M et al. Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance. Cell Metabolism. 2006; 4 (4):303-311 - 123.
Francis GA et al. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Medical Genetics. 2006; 7 :3 - 124.
Hegele RA et al. A frameshift mutation in peroxisome-proliferator-activated receptor-γ in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367). Clinical Genetics. 2006; 70 (4):360-362 - 125.
Monajemi H et al. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-γ. The Journal of Clinical Endocrinology and Metabolism. 2007; 92 (5):1606-1612 - 126.
Lüdtke A et al. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand. Journal of Medical Genetics. 2007; 44 (9):e88 - 127.
Lefterova MI et al. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes and Development. 2008; 22 (21):2941-2952 - 128.
Al-Attar SA et al. Quantitative and qualitative differences in subcutaneous adipose tissue stores across lipodystrophy types shown by magnetic resonance imaging. BMC Medical Imaging. 2007; 7 :3 - 129.
Itabe H et al. Perilipins: A diversity of intracellular lipid droplet proteins. Lipids in Health and Disease. 2017; 16 (1):83 - 130.
Kozusko K et al. Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy. Diabetes. 2015; 64 (1):299 - 131.
Rubio-Cabezas O et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Molecular Medicine. 2009; 1 (5):280-287 - 132.
Keller P et al. Fat-specific protein 27 regulates storage of triacylglycerol. The Journal of Biological Chemistry. 2008; 283 (21):14355-14365 - 133.
Nishino N et al. FSP27 contributes to efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets. The Journal of Clinical Investigation. 2008; 118 (8):2808-2821 - 134.
Albert JS et al. Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes. New England Journal of Medicine. 2014; 370 (24):2307-2315 - 135.
Zolotov S et al. Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy. American Journal of Medical Genetics. Part A. 2017; 173 (1):190-194 - 136.
Wang F et al. Hormone-sensitive lipase deficiency alters gene expression and cholesterol content of mouse testis. Reproduction (Cambridge, England). 2016; 153 (2):175-185 - 137.
Oliveira J et al. Barraquer-Simons syndrome: A rare form of acquired lipodystrophy. BMC Research Notes. 2016; 9 :175 - 138.
Ferrarini A et al. Two new cases of Barraquer–Simons syndrome. American Journal of Medical Genetics Part A. 2004; 126A (4):427-429 - 139.
Martínez E et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. The Lancet. 2001; 357 (9256):592-598 - 140.
Martínez E, Gatell JM. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: The lipodystrophy syndrome. Current Opinion in Infectious Diseases. 1999; 12 (1):13-19 - 141.
Carr A et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. The Lancet. 1998; 351 (9119):1881-1883 - 142.
Okada E, Iwahira Y, Maruyama Y. Buttock deformity repair for congenital generalized lipodystrophy. Plastic and Reconstructive Surgery. 1995; 95 (4):744-746 - 143.
Handelsman Y et al. The clinical approach to the detection of lipodystrophy—An AACE consensus statement. Endocrine Practice. 2013; 19 (1):107-116 - 144.
Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007; 4 (5):675-678 - 145.
Simha V, Garg A. Inherited lipodystrophies and hypertriglyceridemia. Current Opinion in Lipidology. 2009; 20 (4):300-308 - 146.
Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocrine Practice. 2010; 16 (2):310-323 - 147.
McNally M et al. Successful renal transplantation in a patient with congenital generalized lipodystrophy: A case report. American Journal of Transplantation. 2004; 4 (3):447-449 - 148.
Oral EA et al. Leptin-replacement therapy for lipodystrophy. New England Journal of Medicine. 2002; 346 (8):570-578 - 149.
Araujo-Vilar D et al. Recombinant human leptin treatment in genetic lipodystrophic syndromes: The long-term Spanish experience. Endocrine. 2015; 49 (1):139-147 - 150.
Chan JL et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocrine Practice. 2011; 17 (6):922-932 - 151.
Safar Zadeh E et al. The liver diseases of lipodystrophy: The long-term effect of leptin treatment. Journal of Hepatology. 2013; 59 (1):131-137 - 152.
Ebihara K et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. The Journal of Clinical Endocrinology and Metabolism. 2007; 92 (2):532-541 - 153.
Cortés VA et al. Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2−/− lipodystrophic mice independent of hepatocyte leptin receptors. Journal of Lipid Research. 2014; 55 (2):276-288 - 154.
Oral EA, Chan JL. Rationale for leptin-replacement therapy for severe lipodystrophy. Endocrine Practice. 2010; 16 (2):324-333